Evotec and Novo Nordisk in technology development partnership

hanuman

Active member
handshake.jpg


German drug and development company Evotec, has entered into a technology development partnership with Novo Nordisk to support clinical and commercial manufacturing of stem cell-based therapies, Evotec said on Thursday.

Evotec will receive funding for technology development activities in Germany and Italy, research and development funding, an undisclosed upfront payment and possible milestone and royalty payments, it added.

In exchange, Novo Nordisk has an option to obtain exclusive rights to utilise results of the collaboration.

Stem cell-based therapies at Novo Nordisk are still at an exploratory level within diabetes and cardiovascular diseases and the partnership with Evotec is a way to exploit that potential further, Sydbank analysts said.

The partnership might relate to Evotec’s beta-cell implant programme QR-Beta, with the initial upfront sum being a prepayment for capacity and manpower, plus cost margin, according to Warburg Research analyst Christian Ehmann.

“In our estimate, both companies will try to develop a cell-based diabetes cure,” he added.

Shares in Evotec were up 5.6 per cent at 0753 GMT. Novo’s shares were up 1.5 per cent.




The post appeared first on .
 
Top
AdBlock Detected

We get it, advertisements are annoying!

Sure, ad-blocking software does a great job at blocking ads, but it also blocks useful features of our website. For the best site experience please disable your AdBlocker.

I've Disabled AdBlock